Literature DB >> 11131961

Teicoplanin in the treatment of serious infection.

G Schaison1, W Graninger, E Bouza.   

Abstract

The merits and dosing regimens for teicoplanin in the treatment of endocarditis, bacteremia, bone and joint infections, pediatric use, non in-patient use and in the ICU are discussed. Teicoplanin has several advantages over vancomycin in the treatment of serious infections: long half-life, lower nephrotoxicity, and lack of requirement for serum assays. The recommended regimen for teicoplanin is three loading doses of 6 mg/kg (400 mg) q12h, then 6 mg/kg (400 mg) q24h. There is no significant difference in efficacy between teicoplanin and vancomycin when at least 6 mg/kg teicoplanin is used or, in the case of staphylococcal endocarditis, it is given in combination with another antimicrobial. Teicoplanin is effective and safe in staphylococcal infections including endocarditis, osteomyelitis and septic arthritis. The once daily or alternate daily dosage allows home administration of treatment of infections caused by Staphylococcus aureus, including methicillin-resistant strains and enterococci with appreciable savings in hospital costs and improvement in the quality of life.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11131961     DOI: 10.1080/1120009x.2000.11782315

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  5 in total

1.  Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.

Authors:  T Ueda; Y Takesue; K Nakajima; K Ichiki; A Doita; Y Wada; T Tsuchida; Y Takahashi; M Ishihara; H Ikeuchi; M Uchino; T Kimura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-09       Impact factor: 3.267

2.  Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors:  Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

4.  Therapeutic Drug Level Monitoring of Teicoplanin in Korean Pediatric Patients with Normal versus Impaired Renal Function.

Authors:  Joon Sik Choi; Jong Min Kim; Dongsub Kim; Si Ho Kim; Heeyeon Cho; Hyung Doo Park; Soo Youn Lee; Cheol In Kang; Yae Jean Kim
Journal:  J Korean Med Sci       Date:  2020-11-30       Impact factor: 2.153

Review 5.  Antimicrobial Peptides: An Update on Classifications and Databases.

Authors:  Ahmer Bin Hafeez; Xukai Jiang; Phillip J Bergen; Yan Zhu
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.